Metal-dependent protein phosphatases as key regulators of neurodegeneration in parkinson's disease
Active Grant Awarded
- Award ID
- R15NS151713
- Recipient
-
University Of Wisconsin System UEI JBQ9M3PLFDP5
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $576,455
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 6% complete
- Place of performance
- Milwaukee, WI 53201, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, through its National Institute of Neurological Disorders and Stroke, awarded the University of Wisconsin System, doing business as University of Wisconsin-Milwaukee, $576,455 on Sep 17, 2026 under Grant R15NS151713, funded through Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports the research project "Metal-Dependent Protein Phosphatases as Key Regulators of Neurodegeneration in Parkinson's Disease." Aim 1 defines the role of PPM1H-related phosphatases in neuronal survival and in LRRK2-driven neurodegeneration. Aim 2 determines how these phosphatases influence the spread and toxicity of alpha-synuclein. Obligated funds total $576,455. The period of performance runs from the award date through an ultimate completion date of Aug 31, 2029. Place of performance is Milwaukee, WI 53201, USA. The program funds extramural NINDS research into the fundamental structure and function of the brain and nervous system, aimed at reducing the burden of neurological disease.
Description
- Abstract
- Parkinson's disease (PD) is a progressive and currently incurable brain disorder that affects movement and other functions. The disease develops as dopamine-producing nerve cells in a specific region of the brain gradually DIE, leading to symptoms such as tremors, stiffness, and slowed movements. Most cases of PD occur sporadically with no known cause, though aging is the greatest risk factor. About 10% of cases, however, are linked to inherited genetic mutations. Among these, mutations in the LRRK2 gene are the most common and cause a late-onset, familial form of PD. The LRRK2 protein functions as an enzyme that regulates multiple cellular processes. Disease-causing mutations in LRRK2 make the enzyme overactive, which is believed to damage brain cells. Several drugs that inhibit LRRK2 activity are currently in clinical trials, but the precise molecular events leading from LRRK2 overactivity to nerve cell loss are still unclear. One key discovery is that mutant LRRK2 alters the function of other proteins known as RAB gtpases, which control how materials move within cells. Overactive LRRK2 increases the chemical modification (PHOSPHORYLATION) of RAB proteins, a process thought to contribute to PD development. This PHOSPHORYLATION process can be reversed by a group of enzymes called phosphatases, particularly those in the PPM1H subfamily. These phosphatases may help protect neurons by counteracting the harmful effects of LRRK2. However, their role in brain cell health and in the progression of PD has not been established. This proposal aims to determine whether PPM1H-related phosphatases act as key regulators of nerve cell survival and neurodegeneration in PD. • aim 1: define the role of PPM1H-related phosphatases in neuronal survival and in LRRK2-driven neurodegeneration. • aim 2: determine how these phosphatases influence the spread and toxicity of alpha-synuclein, another central protein in PD. • aim 3: evaluate whether enhancing phosphatase activity can protect against nerve cell loss, identifying a potential new therapeutic strategy. Together, these studies will clarify whether PPM1H-related phosphatases represent promising new targets for disease- modifying treatments in PD.
Quick answers
Who received award R15NS151713?
R15NS151713 was awarded to University Of Wisconsin System by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 17, 2026.
How much is award R15NS151713 worth?
$576,455 has been obligated on R15NS151713.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award